Home LiteratureArticle Details
PMID: 18377826 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Immunoregulatory T cells: role and potential as a target in malignancy.

Current oncology reports ·Vol. 10 ·No. 2 ·2008-03-00 ·Pages 130-6

Beyer M, Schultze JL

Abstract

Regulatory T cells (T(reg) cells) are a highly specialized subset of immune cells capable of specifically suppressing autoreactive cells and thereby preventing autoimmunity. T(reg) cells also play an important role in limiting the immune reaction in infectious diseases. In the context of malignancies, however, accumulation of T(reg) cells occurs in the tumor microenvironment. T(reg) cells have been associated with prevention of antitumor immunity and the evasion of efficient recognition of tumor antigens. In the past few years, several approaches have been developed to target and deplete T(reg) cells in the context of tumors. Overall, these interventions have the potential to eliminate T(reg) cells and thereby help strengthen antitumor immunity by vaccination.

MeSH Terms
Animals Cancer Vaccines/immunology Clinical Trials as Topic Forkhead Transcription Factors/metabolism Gene Expression Regulation, Neoplastic Humans Immune System Immunotherapy/methods Mice Neoplasms/immunology,metabolism,therapy T-Lymphocytes, Regulatory/immunology,physiology
Chemicals
Cancer Vaccines FOXP3 protein, human Forkhead Transcription Factors
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Beyer Marc
Molecular Tumor Biology and Tumor Immunology, Clinic I for Internal Medicine, University of Cologne, Kerpenerstr. 62/Haus 16 UG, 50931 Cologne, Germany. [email protected]
Schultze Joachim L
References (50)
50 references, click to expand
  1. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
    Blood. 2007 Nov 1;110(9):3192-201 PMID: 17616639
  2. CCR4 as a novel molecular target for immunotherapy of cancer.
    Cancer Sci. 2006 Nov;97(11):1139-46 PMID: 16952304
  3. Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells.
    J Immunol. 2006 Mar 15;176(6):3301-5 PMID: 16517695
  4. A peripheral circulating compartment of natural naive CD4 Tregs.
    J Clin Invest. 2005 Jul;115(7):1953-62 PMID: 16007258
  5. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model.
    J Immunol. 2007 Jun 1;178(11):6840-8 PMID: 17513732
  6. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.
    Cancer Res. 2006 Apr 15;66(8):4488-95 PMID: 16618776
  7. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
    Leukemia. 2006 Dec;20(12):2162-8 PMID: 17039235
  8. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.
    Cancer Immunol Immunother. 2007 May;56(5):641-8 PMID: 16960692
  9. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
    J Immunol. 1995 Aug 1;155(3):1151-64 PMID: 7636184
  10. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.
    J Exp Med. 1980 Jan 1;151(1):69-80 PMID: 6444236
  11. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.
    Cancer Res. 2006 Jun 1;66(11):5716-22 PMID: 16740709
  12. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.
    Immunity. 2002 Feb;16(2):311-23 PMID: 11869690
  13. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.
    Blood. 2005 Sep 15;106(6):2018-25 PMID: 15914560
  14. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.
    Blood. 2006 May 1;107(9):3639-46 PMID: 16403912
  15. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
    J Immunother. 2002 May-Jun;25(3):207-17 PMID: 12000862
  16. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.
    Cancer Res. 2007 Jan 1;67(1):371-80 PMID: 17210720
  17. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.
    Nat Genet. 2001 Jan;27(1):20-1 PMID: 11137993
  18. Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples.
    J Immunother. 2005 Jul-Aug;28(4):403-11 PMID: 16000960
  19. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    J Immunol. 1999 Nov 15;163(10):5211-8 PMID: 10553041
  20. Regulatory T cells in cancer.
    Blood. 2006 Aug 1;108(3):804-11 PMID: 16861339
  21. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Cancer Res. 2001 Jun 15;61(12):4766-72 PMID: 11406550
  22. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
    J Clin Invest. 2005 Dec;115(12):3623-33 PMID: 16308572
  23. Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy.
    Blood. 2006 Jan 1;107(1):381-8 PMID: 16160005
  24. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.
    J Clin Invest. 2007 Sep;117(9):2570-82 PMID: 17710230
  25. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo.
    J Immunol. 2001 Mar 15;166(6):3789-96 PMID: 11238621
  26. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo.
    Int J Cancer. 2007 Jul 1;121(1):95-105 PMID: 17315190
  27. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.
    J Immunol. 2002 Nov 1;169(9):4811-21 PMID: 12391191
  28. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.
    J Clin Invest. 2003 Nov;112(9):1437-43 PMID: 14597769
  29. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
    J Immunother. 2005 Nov-Dec;28(6):582-92 PMID: 16224276
  30. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.
    Int J Cancer. 2007 Jun 15;120(12):2723-33 PMID: 17315189
  31. Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy.
    J Immunother. 2007 May-Jun;30(4):438-47 PMID: 17457218
  32. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.
    J Exp Med. 2005 Mar 7;201(5):779-91 PMID: 15753211
  33. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  34. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3.
    Nat Immunol. 2007 Mar;8(3):277-84 PMID: 17220892
  35. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.
    J Immunother. 2006 Mar-Apr;29(2):208-14 PMID: 16531821
  36. Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response.
    J Immunol. 1990 Oct 1;145(7):2359-64 PMID: 1975829
  37. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice.
    Nat Immunol. 2007 Feb;8(2):191-7 PMID: 17136045
  38. Foxp3-dependent programme of regulatory T-cell differentiation.
    Nature. 2007 Feb 15;445(7129):771-5 PMID: 17220874
  39. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.
    Blood. 2006 May 15;107(10):3940-9 PMID: 16410445
  40. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
    J Immunol. 2007 Oct 1;179(7):4919-28 PMID: 17878392
  41. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.
    Int Immunol. 2007 Apr;19(4):345-54 PMID: 17329235
  42. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells.
    J Immunol. 2005 Jan 1;174(1):90-8 PMID: 15611231
  43. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours.
    Int J Oncol. 2006 Dec;29(6):1567-71 PMID: 17088998
  44. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.
    J Immunol. 2006 Jul 1;177(1):84-91 PMID: 16785502
  45. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
    J Immunol. 2002 Sep 1;169(5):2756-61 PMID: 12193750
  46. CD4+CD25highFOXP3+ regulatory T cells in peripheral blood are primarily of effector memory phenotype.
    J Clin Oncol. 2007 Jun 20;25(18):2628-30; author reply 2630-2 PMID: 17577047
  47. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta.
    J Exp Med. 2001 Sep 3;194(5):629-44 PMID: 11535631
  48. CD25+ CD4+ regulatory T-cells in cancer.
    Immunol Res. 2005;32(1-3):155-68 PMID: 16106066
  49. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.
    J Exp Med. 2000 Jul 17;192(2):303-10 PMID: 10899917
  50. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.
    Annu Rev Immunol. 2004;22:531-62 PMID: 15032588
Article Info
Journal
Current oncology reports
Abbr.
Curr Oncol Rep
ISSN
1534-6269
DOI
10.1007/s11912-008-0021-z
Email
[email protected]
Published
2008-03-00
Pages
130-6
Language
English
Region
United States
NLM ID
100888967
Subset
IM
External Links
PubMed source DOI: 10.1007/s11912-008-0021-z View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2